LAKE FOREST, Ill., January 03, 2008 /PRNewswire/ -- TAP Pharmaceutical Products Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of TAK-390MR in the treatment of acid related diseases and treatment and maintenance of patients with erosive esophagitis and non-erosive reflux disease. TAK-390MR is a proton pump inhibitor that utilizes a novel delivery system.
"This compound and its novel delivery system is a promising next step in the management of erosive and non-erosive esophagitis," said Nancy Joseph Ridge, M.D., vice president of research and development at TAP. "The development of TAK-390MR is another example of our experience and expertise in this therapeutic area and reinforces our commitment to patients."
The NDA filing, which was entirely electronic (eCTD) from data collection to submission, is based on global studies conducted in more than 20 countries. These studies evaluated more than 6,000 subjects with erosive and non-erosive GERD.
No comments:
Post a Comment